VivoSeq
Dermatology

Burning Mouth Syndrome

19

Pipeline Programs↗

2

Active Trials↗

9

Companies Involved↗

Burning Mouth Syndrome is an emerging landscape with 19 programs across 9 companies. The most active players are Vitae Pharmaceuticals Inc., an Allergan affiliate, AbbVie, Alnylam Pharmaceuticals. 5 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

0/100

Mech. Concentration

36/100

Completion Rate

90/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 2AbbVie logo

AbbVie

2 programs

Phase 3Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 3S

Sebela Pharmaceuticals Development LLC

1 program

Phase 3P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 3V

Viatris Specialty LLC

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical5

Diazepam

Akero Therapeutics

Alpha Lipoic Acid

National Center for Complementary and Integrative Health (NCCIH)

Capsaicin

Averitas Pharma, Inc.

Uréia

University of Sao Paulo General Hospital

Melatonin

Neurim Pharmaceuticals Ltd.

Phase 1
No programs
Phase 22

Onabotulinumtoxina

Vitae Pharmaceuticals Inc., an Allergan affiliate

Botulinum Neurotoxin Type a

DeNova Research

Phase 37

Escitalopram

AbbVie

Duloxetine

Alnylam Pharmaceuticals

Paroxetine

Sebela Pharmaceuticals Development LLC

Pregabalin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Citalopram

AbbVie

Approved5

Clonazepam

Engelhard Arzneimittel GmbH & Co.KG

Topical Placebo Rinse

Federal University of Minas Gerais

Topical Clonazepam Rinse

Federal University of Minas Gerais

Clonazepam Mixed With Mucolox

University of Alberta

Mucolox Alone

University of Alberta

Analysis

Trial Status

18

clinical trials

Completed9 · 50%
Unknown status6 · 33%
Active, not recruiting2 · 11%
Withdrawn1 · 6%

Clinical Trials

Trial Activity

18 trials

Photobiomodulation Therapy vs. Alpha-Lipoic Acid in Burning Mouth Syndrome Treatment
Active, not recruiting·—·N/A·NCT07381361·60 enrolled
Evaluation of the Effect of Different Treatments on Pain Scores and Self-reported Oral Health-related Quality of Life in Individuals With Burning Mouth Syndrome: a Randomized Controlled Clinical Trial
Active, not recruiting·FFederal University of Minas Gerais·Approved·NCT06040190·150 enrolled
Caffeine vs. ALA in BMS Treatment. (BMS: Burning Mouth Syndrome. ALA: Alpha-Lipoic Acid.)
Completed·—·N/A·NCT06195137·130 enrolled
Acupuncture Versus Clonazepam in Burning Mouth Syndrome
Completed·UUniversity of Zagreb·Phase 1·NCT02382029·4 enrolled
Botulinum Toxin in Burning Mouth Syndrome
Completed·PPresidio Ospedaliero Garibaldi-Centro·Phase 2·NCT02964728·6 enrolled
Topical Amitriptyline 1% Gel for the Treatment of Burning Mouth Syndrome
Completed·UUniversidad de Murcia·N/A·NCT07214181·30 enrolled
Opiorphin Levels in Fluids of Burning Mouth Syndrome Patients (OPIODYN)
Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT02686359·42 enrolled
Impact of Diazepam 1% Oral Gel Efficacy in Burning Mouth Syndrome
Completed·UUniversity of Catania·N/A·NCT05872789·40 enrolled
Evaluation of the Effectiveness of the Selected Method of Treatment of Primary Burning Mouth Syndrome
Completed·WWroclaw Medical University·Phase 2·NCT04884503·58 enrolled
Inflammatory Markers in Saliva of Patients With Burning Mouth Syndrome
Completed·UUniversidad de Murcia·N/A·NCT06217731·20 enrolled
The Role of Xerostomia in Burning Mouth Syndrome: Case - Control Study
Completed·UUniversity of Sao Paulo General Hospital·N/A·NCT01754740·38 enrolled
Effectiveness of Mucolox® and Clonazepam in Treatment of Burning Mouth Syndrome
Withdrawn·UUniversity of Alberta·Phase 4·NCT02690844
Impact of Alpha Lipoic Acid Efficacy in Burning Mouth Syndrome
Unknown status·UUniversity of Catania·N/A·NCT05729529·60 enrolled
Head Yuanshi Dian Therapy in Burning Mouth Syndrome
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT04481841·290 enrolled
Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome
Unknown status·FFederico II University·Phase 3·NCT06025474·203 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)